Exploring fasting and a plant-based diet for psoriasis and psoriatic arthritis
The Impact of Fasting on Disease Activity and the Gut Microbiota in Patients with Psoriasis and Psoriatic Arthritis - the RiseFast Pilot Study
This study is testing whether a week of fasting followed by an 11-week plant-based diet can help people with psoriasis and psoriatic arthritis feel better and improve their overall health.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Charite University, Berlin, Germany Academic / other |
| Locations | 1 site (Berlin, State of Berlin) |
| Trial ID | NCT06905028 on ClinicalTrials.gov |
What this trial studies
The RiseFast pilot study investigates the effects of a seven-day fasting period followed by an 11-week plant-based diet on patients with psoriasis and psoriatic arthritis. It aims to assess clinical, metabolic, and immunological changes, focusing on gut microbiota and its relationship with these conditions. The study combines clinical assessments, cytometric profiling, and microbiota analysis to evaluate improvements in disease activity and quality of life. This innovative approach seeks to provide low-cost, accessible therapeutic options with minimal side effects.
Who should consider this trial
Good fit: Ideal candidates include adults with active plaque psoriasis or psoriatic arthritis who have been on stable treatment for at least 12 weeks.
Not a fit: Patients who are pregnant, breastfeeding, underweight, or have severe internal diseases may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could offer new dietary interventions that significantly improve the management of psoriasis and psoriatic arthritis.
How similar studies have performed: While prior studies suggest potential benefits of dietary interventions, the specific effects on psoriatic disease remain largely untested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Active plaque psoriasis (PASI ≥3) or Psoriatic Arthritis fulfilling the Classification Criteria for Psoriatic Arthritis (CASPAR) and not meeting MDA criteria * on stable baseline psoriatic treatment for 12 weeks before enrollment * ≥ 18 years old Exclusion Criteria: * Pregnancy or breastfeeding * underweight (BMI ≤18,5) * eating disorder in the last 5 years * severe internal diseases (e.g. renal insufficiency with creatinine \> 2mg/dl) * current practice of vegan diet or fasting within the past 6 months * use of antibiotics within the past 3 months
Where this trial is running
Berlin, State of Berlin
- Charité - Universitätsmedizin Berlin, Psoriasis-Forschungs- und BehandlungsCentrum — Berlin, State of Berlin, Germany (Recruiting)
Study contacts
- Study coordinator: Anika Rajput Khokhar, MD
- Email: risefast@charite.de
- Phone: +49 30 450 518 329
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.